Classical Hodgkin Lymphoma · line 2 · Pembrolizumab 200 mg IV q3w — r/r cHL post-BV (KEYNOTE-204 schedule)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-PEMBROLIZUMAB-CHL |
| ID | IND-CHL-2L-PEMBROLIZUMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CHL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 2L+ for r/r cHL post-BV. Bridge to alloSCT consolidation standard. Off-label in UA — funding via institutional appeal.
Used By
Algorithms
ALGO-CHL-2L- ALGO-CHL-2L